International Prognostic Index

Revision as of 02:59, 24 August 2015 by Jyostna Chouturi (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

WikiDoc Resources for International Prognostic Index

Articles

Most recent articles on International Prognostic Index

Most cited articles on International Prognostic Index

Review articles on International Prognostic Index

Articles on International Prognostic Index in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on International Prognostic Index

Images of International Prognostic Index

Photos of International Prognostic Index

Podcasts & MP3s on International Prognostic Index

Videos on International Prognostic Index

Evidence Based Medicine

Cochrane Collaboration on International Prognostic Index

Bandolier on International Prognostic Index

TRIP on International Prognostic Index

Clinical Trials

Ongoing Trials on International Prognostic Index at Clinical Trials.gov

Trial results on International Prognostic Index

Clinical Trials on International Prognostic Index at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on International Prognostic Index

NICE Guidance on International Prognostic Index

NHS PRODIGY Guidance

FDA on International Prognostic Index

CDC on International Prognostic Index

Books

Books on International Prognostic Index

News

International Prognostic Index in the news

Be alerted to news on International Prognostic Index

News trends on International Prognostic Index

Commentary

Blogs on International Prognostic Index

Definitions

Definitions of International Prognostic Index

Patient Resources / Community

Patient resources on International Prognostic Index

Discussion groups on International Prognostic Index

Patient Handouts on International Prognostic Index

Directions to Hospitals Treating International Prognostic Index

Risk calculators and risk factors for International Prognostic Index

Healthcare Provider Resources

Symptoms of International Prognostic Index

Causes & Risk Factors for International Prognostic Index

Diagnostic studies for International Prognostic Index

Treatment of International Prognostic Index

Continuing Medical Education (CME)

CME Programs on International Prognostic Index

International

International Prognostic Index en Espanol

International Prognostic Index en Francais

Business

International Prognostic Index in the Marketplace

Patents on International Prognostic Index

Experimental / Informatics

List of terms related to International Prognostic Index

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

The International Prognostic Index (IPI) is a clinical tool developed by oncologists to aid in predicting the prognosis of patients with aggressive non-Hodgkin's lymphoma. Prior to 1993, when the IPI was developed, the primary consideration in assessing prognosis was the Ann Arbor stage alone, but this was increasingly found to be an inadequate means of predicting survival outcomes, and so other factors were studied.

A retrospective analysis was performed on 2031 patients with aggressive non-Hodgkin's lymphoma, of all ages, treated with a doxorubicin-based chemotherapy regimen such as CHOP between 1982 and 1987.[1] Several patient characteristics were analyzed to determine whether they were associated with differences in survival, and the factors that emerged as significant were, in addition to the Ann Arbor stage: age, elevated serum lactate dehydrogenase (LDH), performance status, and number of extranodal sites of disease.

International Prognostic Index

One point is assigned for each of the following risk factors:

  • Age greater than 60 years
  • Stage III or IV disease
  • Elevated serum LDH
  • ECOG/Zubrod performance status of 2, 3, or 4
  • More than 1 extranodal site

The sum of the points allotted correlates with the following risk groups:

  • Low risk (0-1 points) - 5-year survival of 73%
  • Low-intermediate risk (2 points) - 5-year survival of 51%
  • High-intermediate risk (3 points) - 5-year survival of 43%
  • High risk (4-5 points) - 5-year survival of 26%

Although the IPI has shown itself to be a useful clinical tool, widely used by oncologists and a mainstay of risk stratification in clinical trials for lymphoma, it should be kept in mind that it was developed prior to the use of rituximab, which is now included with anthracycline-based combination chemotherapy as of the standard of care in B-cell lymphomas (the majority of non-Hodgkin's lymphomas). Rituximab has dramatically improved the outcomes of lymphoma patients, and its effect on the prognostic value of the IPI is uncertain.

Follicular Lymphoma International Prognostic Index (FLIPI)

Given the success of the IPI for intermediate grade lymphomas, an effort was undertaken to develop a similar prognostic index for the most common low-grade lymphoma, follicular lymphoma. The prognostic factors that emerged from this were: age, stage, number of lymph node areas involved, serum hemoglobin level, and serum LDH.[2]

One point is assigned for each of the following adverse prognostic factors:

  • Age greater than 60 years
  • Stage III or IV disease
  • Greater than 4 lymph node groups involved
  • Serum hemoglobin less than 12 g/dL
  • Elevated serum LDH

The sum of the points allotted correlates with the following risk groups:

  • Low risk (0-1 points) - 5 and 10-year survivals of 91% and 71%, respectively
  • Intermediate risk (2 points) - 5 and 10-year survivals of 78% and 51%, respectively
  • High risk (3-5 points) - 5 and 10-year survivals of 53% and 36%, respectively

References

  1. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329(14):987-94
  2. Solal-Céligny et al. Follicular lymphoma international prognostic index. Blood 2004;104(5):1258-1265.

See Also


Template:WH Template:WikiDoc Sources